Surgery Partners Q2 FY26 net loss widens to $15 million; revenue rises 2.7% to $848.9 million
SGRY•Quarterly results
Surgery Partners posted Q2 2026 revenue up 2.7% to $848.9 million; net loss attributable to shareholders widened to $15 million.
Adjusted EBITDA (non-GAAP) slipped to $125.2 million; adjusted EBITDA margin fell 0.9 percentage points to 14.7%.
Operating trends and outlook
Same-facility revenue rose 5% on 4.8% higher revenue per case; same-facility cases increased 0.3%.
Management highlighted a pending Idaho Falls divestiture to Intermountain Health as part of portfolio optimization and deleveraging.
Full-year 2026 guidance was reaffirmed at $3.35 billion-$3.45 billion revenue, adjusted EBITDA (non-GAAP) of at least $530 million, excluding the pending divestiture.
